Cargando…
Durvalumab: A Review in Advanced Biliary Tract Cancer
Durvalumab (Imfinzi(®)), a therapeutic human monoclonal antibody which binds to and blocks the activity of the immunosuppressive programmed death-ligand 1 (PD-L1) protein, is approved in the USA, EU, Japan and other countries in combination with gemcitabine and cisplatin for adults with advanced bil...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667376/ https://www.ncbi.nlm.nih.gov/pubmed/37943483 http://dx.doi.org/10.1007/s11523-023-01007-y |